Vincenzo De Falco

University of Campania "Luigi Vanvitelli" — Italy

Medicine · Health Sciences

18h-index828citations96works6.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Colorectal Cancer Treatments and Studies(44), Genetic factors in colorectal cancer(19), Cancer Genomics and Diagnostics(15), Cancer Research and Treatments(12), Lung Cancer Treatments and Mutations(10)

Publications96 total

Metastatic Syringocystadenocarcinoma Papilliferum Treated with Enzalutamide: A Case Report and a Review of the Literature
Case Reports in Dermatology·2025Open Access
Supplementary Figure 1 from Antitumor Efficacy of Dual Blockade with Encorafenib + Cetuximab in Combination with Chemotherapy in Human <i>BRAF</i><sup>V600E</sup>-Mutant Colorectal Cancer
2025Open Access
Adipose-tumor crosstalk in colorectal cancer: Identifying (Epi)genetic biomarkers for tumor progression and cachexia
Cell Death and Disease·2025Open Access
Xanthohumol modulate autophagy and ER stress to counteract stemness and enhance cisplatin efficacy in head and neck squamous cell carcinoma
Scientific Reports·2025· 1 citedOpen Access
Off-label drug use in oncology: integrating molecular and genetic analysis in an academic center’s real-world approach
ESMO Real World Data and Digital Oncology·2025· 1 citedOpen Access
Supplementary Figure 1 from Antitumor efficacy of dual blockade with encorafenib plus cetuximab in combination with chemotherapy in human <i>BRAFV600E</i> mutant colorectal cancer.
2024Open Access
Supplementary Figure 1 from Antitumor efficacy of dual blockade with encorafenib plus cetuximab in combination with chemotherapy in human <i>BRAFV600E</i> mutant colorectal cancer.
2024Open Access
Data from Antitumor efficacy of dual blockade with encorafenib plus cetuximab in combination with chemotherapy in human <i>BRAFV600E</i> mutant colorectal cancer.
2024Open Access
Overexpression of CCL-20 and CXCL-8 genes enhances tumor escape and resistance to cemiplimab, a programmed cell death protein-1 (PD-1) inhibitor, in patients with locally advanced and metastatic cutaneous squamous cell carcinoma
OncoImmunology·2024· 4 citedOpen Access
TGF-β Modulated Pathways in Colorectal Cancer: New Potential Therapeutic Opportunities
International Journal of Molecular Sciences·2024· 43 citedOpen Access
Temozolomide based treatment in glioblastoma: 6 vs. 12 months
Oncology Letters·2024· 4 citedOpen Access
Mitochondrial transfer from Adipose stem cells to breast cancer cells drives multi-drug resistance
Journal of Experimental & Clinical Cancer Research·2024· 34 citedOpen Access
Is the use of cetuximab in the first-line treatment of recurrent/metastatic head and neck cancer still important?
Expert Review of Anticancer Therapy·2024Open Access
Prognostic value of diabetes and metformin use in a real-life population of head and neck cancer patients
Frontiers in Medicine·2023· 1 citedOpen Access
Utility of psychotherapy assessed with Kessler scale in a population of cancer patients undergoing systemic oncological treatment: a mono-institutional experience
Chinese Clinical Oncology·2023· 1 citedOpen Access
Panitumumab plus trifluridine/tipiracil as anti‐<scp>EGFR</scp> rechallenge therapy in patients with refractory <scp><i>RAS</i></scp> wild‐type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase <scp>II VELO</scp> trial
International Journal of Cancer·2023· 36 citedOpen Access
Supplementary Figure 1 from Antitumor Efficacy of Dual Blockade with Encorafenib + Cetuximab in Combination with Chemotherapy in Human &lt;i&gt;BRAF&lt;/i&gt;&lt;sup&gt;V600E&lt;/sup&gt;-Mutant Colorectal Cancer
2023Open Access
Data from Antitumor Efficacy of Dual Blockade with Encorafenib + Cetuximab in Combination with Chemotherapy in Human &lt;i&gt;BRAF&lt;/i&gt;&lt;sup&gt;V600E&lt;/sup&gt;-Mutant Colorectal Cancer
2023Open Access
Supplementary Figure 1 from Antitumor Efficacy of Dual Blockade with Encorafenib + Cetuximab in Combination with Chemotherapy in Human &lt;i&gt;BRAF&lt;/i&gt;&lt;sup&gt;V600E&lt;/sup&gt;-Mutant Colorectal Cancer
2023Open Access
SO-24 Panitumumab plus trifluridine/tipiracil as anti-EGFR rechallenge therapy in patients with refractory RAS wild-type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase 2 VELO trial
Annals of Oncology·2023· 2 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

Teresa Troiani(38), Stefania Napolitano(36), Davide Ciardiello(27), Fortunato Ciardiello(22), Emilio Francesco Giunta(22), Erika Martinelli(22), Giulia Martini(21), Vincenzo Famiglietti(19), Pietro Paolo Vitiello(17), Fortunato Ciardiello(17), Pasquale Vitale(14), N. Zanaletti(13), Floriana Morgillo(12), Valentina Belli(10), L. Poliero(9), M. Terminiello(9), Vincenza Caputo(9), Giuseppe Argenziano(9), Davide Ciardiello(8), Ferdinando De Vita(8)